Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDX-1140 · 1 trial · 26 indications
The rates of drug-related adverse events will be summarized and maximum tolerated dose will be determined.
| Arm | Type | Description |
|---|---|---|
| CDX-1140 | EXPERIMENTAL | Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment. |
| CDX-1140 and CDX-301 | EXPERIMENTAL | Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140. |
| CDX-1140 and pembrolizumab | EXPERIMENTAL | Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles. |
| CDX-1140 and chemotherapy | EXPERIMENTAL | Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care. |
| Name | Type | Description |
|---|---|---|
| CDX-1140 | DRUG | CDX-1140 will be administered every 4 weeks in Parts 1, 2 and 4, and every 3 weeks in Part 3. |
| CDX-301 | DRUG | CDX-301 will be injected once a day for five days before Cycles 1 and 2. |
| pembrolizumab | DRUG | pembrolizumab will be administered every 3 weeks. |
| Chemotherapy | DRUG | Gemcitabine and Nab-paclitaxel will be administered on Day 1, Day 8 and Day 15 of each 4 week Cycle. |
Key Inclusion Criteria: 1. Recurrent, locally advanced or metastatic melanoma (including mucosal and/or ocular), bladder/urothelial, non-small cell lung cancer, pancreatic adenocarcinoma, breast, colorectal, gastric, esophageal, renal cell, hepatic, ovarian fallopian or primary peritoneal carcinoma...
Top 20 of 51 competitors
CDX-1140 is an investigational small molecule being studied for the treatment of melanoma. It was evaluated in a Phase 1 clinical trial as a monotherapy or in combination for patients with advanced malignancies, including melanoma. The drug is being developed by Celldex Therapeutics, Inc. and is not yet approved.
CDX-1140 targets CD40, as indicated by the clinical trial title. CD40 is a protein involved in immune system regulation. By targeting CD40, the drug aims to modulate immune responses in the treatment of advanced malignancies, including melanoma.
CDX-1140 is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company. The company's stock ticker is CLDX. The drug is currently in clinical development for oncology indications.
CDX-1140 is in Phase 1 clinical development. It has completed a Phase 1 trial, and the drug remains investigational. It is not FDA approved, and its safety and efficacy are still being evaluated in clinical studies.
CDX-1140 has been studied in one clinical trial with the identifier NCT03329950. This Phase 1 study evaluated CDX-1140 as monotherapy or in combination in patients with advanced malignancies, including melanoma. The trial was completed and enrolled 132 participants in the United States.
CDX-1140 is not the same as CD40; rather, it targets CD40. The clinical trial title refers to CDX-1140 as a CD40-targeting agent. CD40 is the molecular target of the drug, not an alternative name for CDX-1140 itself.